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Abstract
Background: Patients with refractory angina have significant morbidity. This study aimed to
compare two of the treatment options, Spinal Cord Stimulation (SCS) and Percutaneous
Myocardial Laser Revascularisation (PMR) in terms of clinical outcomes and cost-effectiveness.
Methods: Eligible patients were randomised to PMR or SCS and followed up for exercise
tolerance time (ETT), Canadian Cardiovascular Society (CCS) classification and the quality of life
measures SF-36, Seattle Angina Questionnaire and the EuroQoL at 3, 12 and 24 months. Utilities
were calculated using the EQ-5D and these and costs were compared between groups. The
incremental cost-effectiveness ratio (ICER) per QALY for SCS compared to PMR was also
calculated.
Results: At 24 months post-randomisation, patients that had SCS and PMR had similar ETT (mean
difference 0.05, 95% CI -2.08, 2.18, p = 0.96) and there was no difference in CCS classification or
quality of life outcomes. The difference in overall mean costs when comparing SCS to PMR was
GBP5,520 (95% CI GBP1,966 to GBP8,613; p < 0.01) and the ICER of using SCS was GBP46,000
per QALY.
Conclusion: Outcomes after SCS did not differ appreciably from those after PMR, with the former
procedure being less cost-effective as currently applied. Larger studies could clarify which patients
would most benefit from SCS, potentially increasing cost-effectiveness.
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Background
There are estimated to be 30,000–50,000 new patients
with refractory angina pectoris per year in Europe, who are
unsuitable for conventional revascularisation [1]. Proce-
dures aiming to improve quality of life in affected patients
include transmyocardial laser revascularisation (TMR)
and percutaneous myocardial laser revascularisation
(PMR). TMR uses laser ablation to create transmural chan-
nels in ischaemic myocardium via a thoracotomy whilst
the less invasive PMR, delivered via catheter, creates chan-
nels from the endocardium partially through the myocar-
dium. Previous studies comparing TMR and optimal
medical management have shown improved relief of
angina offset by perioperative mortality and morbidity
[2,3]. One UK trial-based analysis concluded that the
technology, with an incremental cost per quality-adjusted
life year gained (QALY) over 12 months of over £200,000,
was not cost-effective in comparison to optimal medical
management [4]. Published clinical evidence suggests that
PMR is an attractive alternative to TMR due to significantly
lower procedural mortality and morbidity [5,6]. One UK
trial-based analysis of PMR versus medical management
produced an estimate over 12 months of over £50,000 per
QALY [7], again above currently accepted UK thresholds.
Spinal cord stimulation (SCS) has been used for many
years in the treatment of chronic pain and, since 1995, for
the treatment of refractory angina pectoris. SCS is a surgi-
cally implanted device that produces a low voltage electri-
cal impulse near the dorsal surface of the spinal cord,
which blocks pain stimuli, leaving the patient with paraes-
thesia instead. Observational and randomized studies of
SCS have found a reduction in angina frequency and an
improvement in quality of life whilst not preventing nor
concealing the symptoms of myocardial infarction [8-13].
Retrospective data from small, uncontrolled studies and
one prospective study in patients with severe angina have
shown that the higher costs of initial SCS treatment may
be offset by fewer subsequent hospital admissions [13-
18]. This study aims to assess the cost-effectiveness of SCS
relative to PMR up to 24 months post-procedure using
prospectively collected data from a randomised control-
led trial in a UK setting.
Methods
Full details of the randomised trial, including detailed
description of the two procedures, baseline characteristics,
and outcome measures are reported elsewhere [18].
Between December 2000 and December 2003, 68 patients
in a tertiary referral centre for cardiovascular disease were
randomised to either SCS with optimal medical therapy
(n = 34) or PMR with optimal medical therapy (n = 34).
Patients were followed up to endpoints at 3, 12 and 24
months. This report focuses on the 24 month results.
Approval was obtained from the local research Ethics
Committee prior to study commencement and informed
consent was obtained.
The primary objective of the study was to compare the
effect of SCS versus PMR on exercise treadmill time using
a modified Bruce Protocol at 24 months post-treatment.
Secondary measures of effectiveness included angina (as
measured by the Canadian Cardiovascular Society classifi-
cation), morbidity/mortality and quality of life, measured
by the disease-specific Seattle Angina Questionnaire
(SAQ) and the generic Short Form-36 (SF-36) and Euro-
QoL questionnaires. The SAQ measures functional status
of patients with angina. SF-36 and EuroQoL are more gen-
eral measures of health status. The SF-36 scores patients
based on 8 broad health outcomes and allows for calcula-
tion of summary physical and mental health scores. Euro-
QoL scores mobility, self-care, usual activities, pain/
discomfort and anxiety/depression and combines these
with self-rated health status, to give a health status score.
The EuroQoL is also used to generate a utility measure for
use in cost-effectiveness analyses. The economic analysis
was designed alongside the clinical study to estimate cost-
effectiveness of SCS relative to PMR, up to 24 months.
Statistical Analysis
Analysis was by intention to treat for subjects for whom
follow-up data were available. Survival was summarized
and compared using Kaplan-Meier methods and the log-
rank test. Adverse events were compared using Poisson
regression. Total exercise time was summarised using the
mean and standard error. Analysis of variance was used to
assess the difference in exercise time between the two
groups adjusting for baseline time. Similar models were
used to assess the difference in health-related quality of
life scales. Since not all patients experienced angina on the
treadmill, the mean time to angina was estimated from
the area under a Kaplan-Meier curve, with angina-free
patients censored at the total exercise time. The change in
angina-free exercise time was calculated from the esti-
mated means and standard errors, accounting for the cor-
relation between baseline and follow up estimated from
those patients who were not censored. The comparison
between groups in angina-free exercise time used Student
t-tests based on these Kaplan-Meier summaries. CCS class
was compared between groups using the Mantel-Haenszel
test for ordered categorical variables. Fisher's exact test was
used to assess differences in the proportion of patients
having a decrease of 2 or more CCS classes (considered
clinically significant), medication usage and proportion
of patients free from angina during exercise. Differences
were considered significant if p < 0.05.
Economic Analysis
An NHS perspective was adopted. Resources included
were those associated with the procedures, cardiac-related
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medication, and cardiac or non-cardiac-related inpatient
or outpatient admissions, up to 24 months after proce-
dure. Resources consumed solely as a result of the research
element of the trial protocol were excluded. All resources
were valued at 2005/06 costs.
SCS and PMR procedures
Both procedures were costed according to the most rele-
vant elective inpatient Health Resource Group (HRG) fin-
ished consultant episodes [19]. The SCS procedure was
costed according to either HRG A08: Percutaneous Image
Controlled Pain Procedures or HRG R11: Spinal Cord Sur-
gery. If a patient was admitted to hospital for two days or
more they were assigned to the HRG R11 (n = 30) and for
less than two days they were assigned to HRG A08 (n = 2).
These HRG costs were based on standard resource use
items including theatre and staff time, pathology, radiol-
ogy and ECG tests. For both procedures, the cost of rele-
vant procedure-related equipment was added to generate
a total mean cost per patient. Patient specific data were
collected on length of stay for the immediate period of
hospitalisation and appropriate cardiac ward bed day
costs were assigned. For further details of the main catego-
ries of resource use and costs, see table 1.
Cardiac-related medication
Use of major cardiac-related medication were recorded for
all patients. Since information on dosage was not availa-
ble, an average dosage based on clinical opinion was
applied and a monthly cost was calculated (see Table 1).
If a patient stopped taking a drug between follow up visits,
it was assumed that cessation occurred at the mid-point
between the visits. Costing to 24-months was carried out
using the British National Formulary [20].
Inpatient and outpatient episodes
Length of stay and diagnosis were recorded for all inpa-
tient episodes. For cardiac-related inpatient episodes, the
mean national cost of the relevant HRG finished consult-
ant episode was applied, adjusted for actual length of stay
[19]. Papworth hospital costs of overnight admissions for
cardiac-related investigations were adjusted to a national
level by the National Reference Cost Index. Cardiac-
related inpatient episodes for crossover patients (two SCS
and four PMR) during the 12 – 24 month follow-up
period were included. The mean national cost of the rele-
vant HRG finished consultant episode was applied for
non-cardiac-related inpatient episodes.
Patient Utility and QALYs
At baseline, and 3, 12 and 24 months post-procedure,
patients completed the EuroQol questionnaire. Each
patient's self-reported classification was valued according
to the tariff of UK population values by Dolan et al. [21].
Assuming a linear change in values between time points,
patient specific utilities up to 24 months from randomisa-
tion were calculated. For missing EQ-5D data, values were
interpolated between adjacent visits. Where 24-month
data were missing, the value from the last visit was carried
forward. A utility value of zero was applied to patients
who died.
The QALYs to 24 months from randomisation were calcu-
lated as the area under the utility curve to 24 months or
time of death. General linear modelling was used to adjust
Table 1: Main resource use and cost categories
Resource Use Cost applied* Unit Cost Source
Procedures:
Cardiac Ward Bed day P £285 Papworth NHS Trust
SCS Equipment – Electrode/IPG F £8,240 Papworth NHS Trust
PMR Equipment – (Laser/Catheter) F £5,755 Papworth NHS Trust
SCS Procedure (HRG: A08) F £3,040 Papworth NHS Trust
SCS Procedure (HRG: R11) F £3,685 Papworth NHS Trust
PMR Procedure – Catheter Lab F £197 Papworth NHS Trust
Pathology/Radiology Tests (Both procedures) P £45 Papworth NHS Trust
Cardiac-related medication (cost per month):
Calcium Antagonists -Atenolol (50 mg) P £0.90 BNF 200617
Long-Acting nitrates – Imdur (60 mg) P £12 BNF 2006
Short-Acting nitrates – GTN spray (1200 mcg) P £1.40 BNF 2006
ACE Inhibitors – Lisinopril (10 mg) P £1.80 BNF 2006
Diuretics – Frusemide (40 mg) P £1.10 BNF 2006
Statins – Simvastatin (20 mg) P £1.60 BNF 2006
*P = patient, F = fixed
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follow-up utility values for baseline. To estimate confi-
dence intervals, without assuming any parametric form
for cost and QALY distributions, bootstrapping was used
(1000 samples) [22]. Costs and utilities incurred between
12 and 24 months were discounted at an annual rate of
3.5% based on the latest NICE guidance [23]. As a small
number of patients in both treatment groups were cen-
sored prior to 24-month follow-up, published methods to
deal with censored data were applied to the cost and
QALY estimates [24]. The Incremental Cost-Effectiveness
Ratio (ICER) was calculated as the difference in mean cost
divided by the difference in mean QALY. Uncertainty due
to parameter estimation was demonstrated by calculation
of the cost-effectiveness acceptability curve. This curve
plots the probability that SCS is cost-effective, compared
with PMR, against the maximum societal willingness to
pay for 1 QALY gain.
Results
Recruitment and follow-up
Trial methods and clinical results for the first 12 months
have been published [18]. From 125 patients assessed for
eligibility, sixty-eight patients were recruited and ran-
domised (Figure 1). At baseline, patients in the treatment
groups had similar mean age (64.2 vs 62.9 years), sex dis-
tribution (85% vs 91% male), CCS class (Class III: 65% vs
74%; Class IV: 35% vs 26%) and anti-anginal medication.
During 24 months of follow up, of the patients allocated
to SCS, five died, three withdrew from the trial, three were
unable to do the 24 month exercise test, and one test was
terminated due to equipment malfunction (3 patients
provided quality of life data), leaving 22 with exercise test
data. Of the patients allocated to PMR, two died during
follow up, 5 withdrew from the trial (1 later died more
than 24 months post-randomization) and 6 could not
perform an exercise test at 24 months (4 of whom pro-
vided quality of life data), leaving 21 patients with exer-
cise test data at 24 months (see Figure 1 for further
details). Resource use data were available for all partici-
pants.
Adverse events
There were eight deaths to the end of September 2005, five
in the SCS group and three in the PMR group (one patient
had previously withdrawn). Causes of death (days post
procedure) were ischaemic heart disease (18), metastatic
squamous cell carcinoma (442), presumed malignancy
(630) and two acute MI (589 and 660) in the SCS group
and stomach carcinoma (430), ischaemic heart disease/
MI (490) and unknown (683) in the PMR group. Survival
was 85% at 24 months in the SCS group and 94% at 24
months in the PMR group (p = 0.46).
Between randomization and procedure, one SCS patient
had a bout of unstable angina requiring hospitalization.
Another patient experienced a bent lead during SCS
implantation, which was classed as an event of moderate
severity. In the first year post-procedure, there were 75
non-fatal, adverse events in 32 patients and in the second
year there were 53 in 30 patients (Table 2). The SCS group
reported more adverse events than the PMR group in the
first year but less in the second year (relative rates [RR] 1.5,
95% CI 0.9, 2.3, p = 0.10 and 0.8, 95% CI 0.5, 1.4, p =
0.44). Over the 24-month period, 36 events in the SCS
group and 41 events in the PMR group were disease-
related (RR 0.9, 95% CI 0.6, 1.3, p = 0.51). There were 25
SCS related events up to 24-months, four of which
occurred in patients who had crossed over from PMR.
There were four events related to the PMR procedure up to
24 months, one of which occurred in a patient that had
crossed over. Of all the adverse events, 62 in the SCS
group and 54 in the PMR group were classed as severe (RR
1.1, 95% CI 0.8, 1.6, p = 0.53) (Table 2).
Exercise Tolerance Tests and CCS class
The results from the exercise tolerance tests are summa-
rised in Table 3. Adjusting for baseline, there was little dif-
ference in exercise time between the two groups at 24
months (Table 3). Mean time to angina was also similar
in the two groups.
At 24 months there was no significant difference between
the treatment groups in CCS class. A greater number of
SCS patients had a decrease of two or more CCS classes,
although this result was not statistically significant.
Health-related quality of life
Figures 2 and 3 show the mean difference between groups
in health-related quality of life measures at 3, 12 and 24
months adjusting for baseline. For most scales, both
groups reported improvements from baseline (data not
shown), but there were no significant differences between
the groups at follow up (all p ≥ 0.08, Figures 2 &3).
Medication
As at baseline, all patients were being treated with maxi-
mally tolerated anti-anginal medication at 24 months.
Among the patients who completed the exercise test, there
were no significant differences between SCS and PMR
groups in use of Beta Blockers (91% vs. 81%), Calcium
Antagonists (68% vs. 71%), ACE Inhibitors (46% vs.
57%), long acting Nitrates (77% vs. 91%) short acting
Nitrates (100% vs. 86%) Aspirin (77% vs. 86%) or Nic-
orandil (77% vs. 91%) (all p ≥ 0.11).
Resource use and costs
Information on resource use and costs to 24 months is
presented in Table 4.
Trials 2008, 9:40 http://www.trialsjournal.com/content/9/1/40
Page 5 of 11
(page number not for citation purposes)
CONSORT diagram showing the flow of participants through the trial comparing SCS with PMRFigure 1
CONSORT diagram showing the flow of participants through the trial comparing SCS with PMR.
Failed inclusion criteria (n=48)
Not suitable on presentation (n=9) 
Assessed for eligibility (n=125) 
Allocated to PMR (n=34)   
Received PMR (n=33) 
(One refused procedure and 
withdrew)
Randomised (n= 68) 
Lost to follow up for 24m (n=9) 
Reasons:
Patient withdrew (n=1) 
Patient died (n=2) 
No primary endpoint data (n=6) 
Lost to follow up for 24m (n=8) 
Reasons:
Patient withdrew (n=1) 
Patient died (n=4) 
No primary endpoint data (n=3) 
(And patient with no 12m endpoint 
also had no 24mo endpoint) 
Primary outcome analysis (n=21) 
Allocated to SCS (n=34) 
Received SCS (n=32) 
(One refused procedure and 
withdrew)
(One had PMR)
Lost to follow up for 12m (n=4) 
Reasons:
Patient withdrew (n=2) 
Patient died (n=1) 
No primary endpoint data (n=1) 
Lost to follow up for 12m (n=4) 
Reasons:
Patient withdrew (n=4) 
No primary endpoint data (n=0) 
Primary outcome analysis (n=22) 
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Initial Procedure Costs
The mean cost per patient of the PMR (laser equipment
and catheter) and SCS (implantable pulse generator, elec-
trode) equipment was £5,755 and £8,239 respectively.
Other resources used during the procedure (staff time,
overheads, catheter lab, theatre time etc) were much
greater for SCS (£4,353 versus £326), mainly because it
was a longer procedure (two to three hours on average)
which takes place in theatre (based on British Pain Society
recommendations for best clinical practice [25]) whilst
the shorter PMR procedure (90 minutes) takes place in the
catheter lab. Length of hospital inpatient stay (and there-
fore cost of stay) was similar: mean 2.9 days for PMR and
2.7 days for SCS. The mean total procedure cost was
£6,892 (95% CI £6,757 to £7,087) for PMR and £13,350
(95% CI £13,112 to £13,491) for SCS.
Table 2: Adverse events *
Months 0–12 post-
procedure
Months 13–24 post-
procedure
SCS PMR SCS PMR
Disease-related
Unstable angina 16 (10) 16 (7) 7 (5) 12 (4)
Myocardial infarction 4 (3) 1 (1) 1 (1) 1 (1)
Loss of pain relief/angina worse 5 (5) 3 (2) 3 (3) 8 (6)
Total disease related 25 (18) 20 (10) 11 (9) 21 (11)
SCS related: Infection of SCS system 0 NA 0 2 (2)
Undesirable change in stimulation 7 (5) NA 5 (5) 2 (1)
Pain at neurostimulator site 5 (3) NA 0 0
Neurostimulator migration 2 (2) NA 1 (1) 0
Lead migration 1 (1) NA 0 0
PMR related: Femoral pseudoaneurysm 0 1 (1) 0 0
Groin haematoma 1 (1) 2 (2) 0 0
Other 4 (3) 7 (7) 7 (5) 4 (4)
Total 45 (17) 30 (15) 24 (18) 29 (12)
Total excluding SCS/PMR related 29 (14) 27 (14) 18 (12) 25 (11)
Severity
Mild 2 (2) 2 (2) 0 0
Moderate 5 (5) 0 0 3 (2)
Severe** 38 (15) 28 (15) 24 (18) 26 (11)
Total 45 (17) 30 (15) 24 (18) 29 (12)
*Data are number of events (number of patients), NA means Not Applicable.
**Severe included events which: required hospital admission and/or surgery, prolonged hospital stay, or were life-threatening or fatal.
Table 3: Comparisons between SCS and PMR in mean exercise tolerance and CCS at 24 months
SCS PMR Difference adjusted
for baseline 95%CI
p
Exercise test at 24 months (n = 22) (n = 21)
Mean (SEM) exercise time 7.04 (0.76) 7.70 (0.88) 0.05 (-2.08, 2.18) 0.96
Mean* (SEM) time to angina 7.69 (1.08) 7.57 (1.08) 0.91 (-2.67, 4.49) 0.62
No angina during exercise 11 (50%) 7 (33%)
CCS class at 24 months (n = 22) (n = 21)
1 3 (14%) 2 (9%) 0.55**
2 9 (41%) 9 (43%)
3 8 (36%) 6 (29%)
4 2 (9%) 4 (9%)
Change in CCS >= 2 classes
No 15 (68%) 17 (81%) 0.49**
Yes 7 (32%) 4 (19%)
* Calculated from area under Kaplan-Meier time to angina curves (some patients stopped exercising before onset of angina). Comparisons based on 
change from baseline and within patient correlation estimated from uncensored patients from both groups combined (ρ = 0.28).
**p-values unadjusted for baseline
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Follow-up Costs
The costs of cardiac-related medication and cardiac and
non-cardiac inpatient episodes, including subsequent
SCS/PMR procedures, were similar (Table 4). The mean
overall difference between the two groups for non-proce-
dural costs favoured SCS but was not significant at -£461
(95%CI -£4,399 to £1,964).
Overall costs SCS vs. PMR
The difference in overall mean costs to 24 months of
£5,520 (95% CI £1,966 to £8,613; p < 0.01) indicates that
the additional cost of the SCS procedure was not offset by
the small reduction in non-procedure costs over two
years.
Utility
There were no significant differences in overall utility at
24 months between groups after adjustment for baseline
(Table 4). There was a mean QALY difference favouring
SCS of 0.12 (95% CI: -0.04 to 0.30; p > 0.1). This differ-
ence equates to approximately 6 weeks in perfect health
gained from the use of SCS over PMR (95% CI: -2 weeks
to 16 weeks).
Cost-Utility
The mean incremental cost per QALY of using SCS was
£46,000 over 24 months. Figure 4 shows the cost-effec-
tiveness acceptability curve. Taking £30,000 per QALY as
the maximum acceptable in the UK, which is broadly in
line with NICE guidance [26,27], the probability of SCS
being cost-effective compared with PMR over a two year
time period is approximately 30%.
Sensitivity Analysis
This was a relatively small trial taking place within a single
centre, resulting in imprecise estimates of costs and out-
comes. To assess the impact of some of the trial parame-
ters and the results' relevance to other settings, sensitivity
analyses were conducted including:
(i) the effect of lower capital cost of the SCS equipment or
more intensive use (i.e. higher patient throughput) by
Mean difference between SCS and PMR in EQ-5D scores at 3, 12 and 24 months post-procedure (values above 0 favour SCS)Figure 2
Mean difference between SCS and PMR in EQ-5D scores at 3, 12 and 24 months post-procedure (values above 
0 favour SCS). * Adjusted for baseline.
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halving SCS equipment costs to £4,120 per case. This
resulted in a smaller difference in mean costs (£2,340)
and a lower ICER of £19,500 per QALY.
(ii) the effect of carrying out SCS in the catheter lab
instead of in theatre, reducing total cost of the procedure
by approximately £2,500. Similarly, this results in a lower
difference in mean cost (£2,262) and a lower ICER of
£18,850 per QALY.
(iii) combining (i) and (ii) resulted in SCS being cheaper
than the PMR strategy (by approximately £1,700) and
more effective.
(iv) sensitivity of the results to deaths was explored. Omis-
sion of these deaths (5 SCS; 2 PMR) results in a slightly
higher mean QALY difference in favour of SCS of 0.19
reducing the ICER to approximately £30,000 per QALY.
(v) the SF-36 allows calculation of an alternative utility
measure (SF-6D) [28,29], resulting in mean QALY differ-
ence favouring SCS of 0.011 (95% CI: -0.12 to 0.13; p >
0.1), and a much higher incremental cost per QALY of
approximately £500,000.
Discussion
Clinical Results
This study compared two treatments for refractory angina
and reported the results of follow-up at 24 months. SCS
patients had greater time to angina and lower CCS class at
3 months, but these differences were not maintained at 12
months [18], nor at 24 months, as shown here. It was
thought that differences between SCS and PMR groups
might increase over time as follow up continued, but the
differences between the groups were smaller at 24 months
(0.05 minutes in exercise time and 0.91 minutes to angina
versus 0.59 and 1.23 at 12 months).
Mean difference between SCS and PMR in SF-36 and SAQ scales at 3, 12 and 24 months post-procedure, adjusted for baseline scores (values above 0 favour SCS)Figure 3
Mean difference between SCS and PMR in SF-36 and SAQ scales at 3, 12 and 24 months post-procedure, 
adjusted for baseline scores (values above 0 favour SCS). SF36 – 36-item short form survey; PCS – physical component 
score; MCS – mental component score; SAQ – Seattle Angina Questionnaire, ECS – Exertional capacity scale; ASS – Anginal 
stability scale; AFS – Anginal frequency scale; TSS – Treatment satisfaction scale; DPS – Disease perception scale.
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Past studies have shown PMR to be a safer and more cost-
effective option than TMR. It was thought that the
increased costs of SCS might be offset by decreased mor-
bidity and hospital admission costs compared to PMR.
Patients did have non-significant improvements in exer-
cise and quality of life outcomes with SCS over PMR, but
these were small and not statistically significant, and costs
were higher for SCS patients. In addition, while SCS is less
invasive than TMR, it is more invasive than PMR.
Table 4: Mean costs and QALYs to 24 months post-randomisation
Resource SCS (n = 34)
Mean cost per patient (95% CI)
PMR (n = 34)
Mean cost per patient (95% CI)
Mean cost difference
(95% CI)
PMR/SCS Equipment* £8,239 £5,755
PMR/SCS Procedure £4,353 (£4,046 to £4,397) £326 (£307 to £353)
PMR/SCS LOS £756 (£685 to £872) £812 (£695 to £988)
Total SCS/PMR procedure cost £13,350 (£13,112 to £13,491) £6,892 (£6,757 to £7,087) £6,459 (£6,196 to £6,642) †
Non-procedural cost £957 (£839 to £1,088) £1,025 (£891 to £1,147)
Cardiac-related medication £3,294 (£2,076 to £5,844) £3,645 (£1,638 to £7,537)
Cardiac inpatient episodes £97 (£22 to £281) £146 (£18 to £492)
Non-cardiac inpatient episodes £4,350 (£3,064 to £6,873) £4,811 (£2,750 to £8,633)
Total non-procedural costs -£461 (-£4,399 to £1,964) ‡
Overall treatment costs at 24 months** £17,736 (£16,398 to £19,202) £12,215 (£9,603 to £15,448) £5,520 (£1,966 to £8,613)†
Utility SCS (n = 34) PMR (n = 34) QALY difference
Mean QALY per patient (95% CI) Mean QALY per patient (95% CI) (95% CI)
QALYs up to 24 months** 1.19 (1.040 to 1.319) 1.07 (0.960 to 1.178) 0.12 (-0.04 to 0.30)‡
*Fixed cost applied to all patients; **Overall costs and QALYs taking account of censoring; † p < 0.01; ‡ p > 0.1
Cost-effectiveness acceptability curveFigur  4
Cost-effectiveness acceptability curve.
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Economics
The additional NHS cost of using SCS versus PMR was
estimated to be £5,520. When combined with the small
health benefits observed, the mean incremental cost per
QALY was £46,000. Since this is based on early experience
within a specialist tertiary centre, results may well
improve with greater experience over time. Exploring the
cost-effectiveness of SCS versus PMR in the first and sec-
ond half of the study suggested there was an improvement
over time, which could be indicative of a learning curve
effect. For patients recruited during 2000/01, the ICER
was estimated at £230,000 per QALY (95% CI: -
£2,670,000 to £590,000) whereas for 2002/03, the ICER
was estimated at £18,000 per QALY (95% CI: -£21,000 to
£51,000). This improvement can largely be explained by
better outcomes, in terms of survival and QoL, experi-
enced by SCS patients in the second half of the study. Out-
comes may not, however, be as good in a non-specialist
centre.
A limitation is that the small sample size in this study
resulted in low precision, in particular in the case of the
QALY estimates, which showed no significant difference
between the two groups. Given that we did not observe a
difference, there is no a priori reason to assume that the
relative cost-effectiveness of the two procedures would
change if observed over a longer period.
Even if the (most optimistic) ICER estimate of £30,000
per QALY is the most appropriate, the issue of how SCS
fits in to the overall picture in terms of cost-effectiveness
of interventions for treatment of refractory angina is not
clear. In this study, SCS was compared to PMR as the next
best treatment to estimate cost-effectiveness. In a previous
cost-effectiveness analysis, PMR was compared against
optimal medical management producing an ICER over 12
months of over £50,000 per QALY [7], a figure well above
the current maximum thresholds in the UK. Here, SCS
was compared to PMR rather than optimal medical man-
agement thus raising the question of whether SCS was
compared with the next best alternative treatment, at least
from the cost-effectiveness perspective. Given that neither
TMR nor PMR were cost-effective over 12 months in com-
parison with optimal medical management, one might
presume that SCS is unlikely to prove cost-effective
against medical management. This should be confirmed
by comparing SCS with medical management either
directly within a randomised controlled trial, or indirectly
via economic modelling. In addition, we saw lower clini-
cal effectiveness here than has been seen in other studies,
however, this is likely due to over-estimation of the effec-
tiveness of treatments in observational studies due to
selection bias.
Conclusion
The results suggest that there is little difference between
SCS and PMR with respect to clinical and patient out-
comes. Larger studies of SCS are needed to determine
which patients benefit most from SCS; targeting the treat-
ment to these patients could make SCS more cost-effec-
tive.
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